Open an account

LivaNova

LIVN · NASDAQ

$80.90−$0.37 (−0.46%)TodayMarket closed ·
Prev close $81.27

About LIVN

LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. The firm designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.

Employees
3,300
Headquarters
London
Listed
Oct 19, 2015
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
livanova.com

LIVN key statistics

Market cap
4.46B
Price-earnings ratio
24.04
Dividend yield
—
Average volume
636.79K
Volume
568.94K
Open price
$80.98
High today
$81.77
Low today
$80.33
52 Week high
$85.76
52 Week low
$48.82

LivaNova (LIVN) at a glance

LivaNova (LIVN) last traded at $80.90, with a market cap of 4.46B and a price-to-earnings ratio of 24.04.

Today the stock has traded between $80.33 and $81.77. The current price is 0.7% above the day's low and 1.1% below its high.

Volume so far is 568.94K shares, in line with the average of 636.79K shares a day.

Over the past year LivaNova has ranged from $48.82 to $85.76, and now sits 87% of the way up that range.

LivaNova met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $1.26 per share against an estimate of $1.12.

The average analyst price target is $91.03, 12.5% above the current price, from 9 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

78%of 9 analyst ratings say Buy
  • Buy77.8%
  • Hold22.2%
  • Sell0.0%
Price target · 12 analystsAvg $91.03
Low
$75.75
Now
$80.90
High
$105.00

LIVN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 14.0% on average.

  1. Q3 FY24: reported $0.90 per share against an estimate of $0.7312
  2. Q4 FY24: reported $0.81 per share against an estimate of $0.8173
  3. Q1 FY25: reported $0.88 per share against an estimate of $0.7777
  4. Q2 FY25: reported $1.05 per share against an estimate of $0.8727
  5. Q3 FY25: reported $1.11 per share against an estimate of $0.9374
  6. Q4 FY25: reported $0.86 per share against an estimate of $0.8314
  7. Q1 FY26: reported $0.98 per share against an estimate of $0.9147
  8. Q2 FY26: reported $1.26 per share against an estimate of $1.12

LIVN news

  • Press releaseBusiness Wire

    Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova’s VNS Therapy for Drug-Resistant Epilepsy

  • Press releaseBusiness Wire

    LivaNova to Present at UBS, Wolfe, Stifel, and Jefferies Healthcare Conferences in November

  • Press releaseBusiness Wire

    LivaNova to Announce Third-Quarter 2026 Results

  • Press releaseBusiness Wire

    LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September

  • Press releaseBusiness Wire

    LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

  • Press releaseBusiness Wire

    LivaNova to Announce Second-Quarter 2026 Results

  • Press releaseBusiness Wire

    LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea

  • Press releaseBusiness Wire

    Jette Nygaard-Andersen Joins LivaNova Board as a New Director

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.